Uncovering Novel Psychoactive Substance Biomarkers Using Diagnostic Fragment Screening

Identifying fentanyl analogs and other novel psychoactive substances (NPS) in the recreational drug market poses a significant analytical challenge for forensic toxicology laboratories.

In this webinar, two expert speakers will showcase how accurate mass diagnostic fragments of fentanyl and other analogs can be utilized to identify new fentanyl analog biomarkers. They will demonstrate the efficiency and simplicity of SCIEX Molecule Profiler software as a comprehensive and user-friendly platform for identifying novel metabolites, precursors and impurities of emerging drugs.

Attend this webinar to learn about:

• The challenges associated with the identification of fentanyl analogs and other NPS emerging on the recreational drug market
• The use of accurate mass diagnostic fragments for the identification of drug biomarkers
• The streamlined process of identifying drug biomarkers using diagnostic fragment screening with SCIEX Molecule Profiler software
• The benefits of this approach for the identification of novel metabolites, precursors and impurities of emerging new drugs

Presenter: Dr. Aaron Stella (R&D Scientist, SCIEX)

Presenter: Dr. Karl Oetjen (Senior Scientist, Technical Marketing, SCIEX)